Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.

Growing evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors across multiple malignancies. However, evidence in extensive-stage small cell lung cancer (ES-SCLC) remains limited to a single East Asian cohort, and independent validation in other populations i